LQDA Logo

Liquidia Corporation (LQDA) 

NASDAQ
Market Cap
$901.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
26 of 774
Rank in Industry
22 of 433

Largest Insider Buys in Sector

LQDA Stock Price History Chart

LQDA Stock Performance

About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Insider Activity of Liquidia Corporation

Over the last 12 months, insiders at Liquidia Corporation have bought $15.43M and sold $3.5M worth of Liquidia Corporation stock.

On average, over the past 5 years, insiders at Liquidia Corporation have bought $12.31M and sold $7.68M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $25M. Caligan Partners LP () — $9.43M. JEFFS ROGER (Chief Executive Officer) — $4M.

The last purchase of 337,078 shares for transaction amount of $3M was made by Manning Paul B (director) on 2024‑09‑12.

List of Insider Buy and Sell Transactions, Liquidia Corporation

2024-10-28SaleChief Business Officer
459
0.0006%
$11.31$5,190-2.81%
2024-10-18SaleChief Medical Officer
2,526
0.003%
$11.19$28,266-4.04%
2024-10-14SaleChief Executive Officer
8,053
0.0106%
$11.11$89,450-2.69%
2024-10-14SaleGeneral Counsel
2,576
0.0034%
$11.11$28,613-2.69%
2024-10-14SaleCFO and COO
3,892
0.0051%
$11.11$43,231-2.69%
2024-10-14SaleChief Medical Officer
2,260
0.003%
$11.11$25,103-2.69%
2024-10-14SaleChief Commercial Officer
1,527
0.002%
$11.11$16,961-2.69%
2024-10-14SaleChief Business Officer
1,146
0.0015%
$11.11$12,729-2.69%
2024-09-12Purchasedirector
337,078
0.4019%
$8.90$3M+9.46%
2024-09-03SaleGeneral Counsel
710
0.001%
$9.50$6,745+12.86%
2024-09-03SaleCFO and COO
1,079
0.0015%
$9.50$10,250+12.86%
2024-09-03SaleChief Commercial Officer
546
0.0007%
$9.50$5,187+12.86%
2024-09-03SaleChief Business Officer
455
0.0006%
$9.50$4,322+12.86%
2024-08-30SaleSee Remarks
150,000
0.1953%
$9.51$1.43M+7.99%
2024-08-30PurchaseSee Remarks
150,000
0.1953%
$9.51$1.43M+7.99%
2024-07-26SaleChief Business Officer
1,833
0.0024%
$11.44$20,970-11.69%
2024-07-19SaleChief Medical Officer
1,873
0.0025%
$11.13$20,846-6.45%
2024-07-12SaleChief Executive Officer
8,053
0.0107%
$12.53$100,9040.00%
2024-07-12SaleGeneral Counsel
1,985
0.0026%
$12.53$24,8720.00%
2024-07-12SaleCFO and COO
3,906
0.0052%
$12.53$48,9420.00%

Insider Historical Profitability

17.92%
Caligan Partners LPSee Remarks
6994997
8.2647%
$10.6521
Manning Paul Bdirector
816311
0.9645%
$10.6540+16.39%
JEFFS ROGERChief Executive Officer
812193
0.9596%
$10.6554+34.86%
Schundler RussellGeneral Counsel
486048
0.5743%
$10.6526+38.84%
Kaseta MichaelCFO and COO
311076
0.3675%
$10.6526+33.43%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Caligan Partners LP$152.82M13.5710.36M0%+$040.4
Patient Square Capital Lp$105.94M9.47.18MNew+$105.94M45.11
BlackRock$55.28M4.913.75M+6.18%+$3.22M<0.01
The Vanguard Group$42.59M3.782.89M+1.52%+$639,441.99<0.01
Kynam Capital Management Lp$33.16M2.942.25M-16.68%-$6.64M0.42
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.